Literature DB >> 18844220

How many cervical cancers are prevented by treatment of screen-detected disease in young women?

Peter Sasieni1, Alejandra Castanon, D Max Parkin.   

Abstract

Others have argued that as many as a third of women treated for high-grade cervical intraepithelial neoplasia (CIN) would have developed cervical cancer in the absence of screening and treatment. Under various assumptions and using past data on CIN grade 3 (CIN3) registrations in England and Scotland, we estimate what cervical cancer rates would have been in the absence of screening. Data on registrations of cervical carcinoma in situ for England and Scotland were used to project the additional numbers of invasive cervical cancers that would have resulted had the carcinoma in situ not been treated. We compare the resulting cervical cancer rates (under different models) with rates recorded in Cancer Incidence in 5 Continents. In order for the projected rates in England and Scotland at ages 20-24 not to be exceptionally high compared to maximum recorded rates for each registry in Cancer Incidence in 5 Continents, the progression rate from CIN3 to invasive cancer in women aged 20-24 should not exceed 1% per year. Similar progression rates were reasonable for women aged 25-29. Under the previously accepted assumption of 4.33% progression per year, cervical cancer rates in women aged 20-29 in both England and Scotland would have been 2-5 times greater than any observed rate (other than one registry, based on just 4 cases). From this analysis, at most 1.5% of women treated (equivalent to 3% of CIN3 registrations) would have had cancer by age 25, whereas it is reasonable to assume that over half of them would have regressed by age 25. Copyright (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2009        PMID: 18844220     DOI: 10.1002/ijc.23922

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  Cervical cancer in rural India.

Authors:  Anthony B Miller
Journal:  Nat Rev Clin Oncol       Date:  2009-07       Impact factor: 66.675

Review 2.  Clinical application of DNA ploidy to cervical cancer screening: A review.

Authors:  David Garner
Journal:  World J Clin Oncol       Date:  2014-12-10

3.  Practice improvement in cervical screening and management (PICSM): symposium on management of cervical abnormalities in adolescents and young women.

Authors:  Anna-Barbara Moscicki; J Thomas Cox
Journal:  J Low Genit Tract Dis       Date:  2010-01       Impact factor: 1.925

Review 4.  New strategies for human papillomavirus-based cervical screening.

Authors:  Attila Lorincz; Alejandra Castanon; Anita Wey Wey Lim; Peter Sasieni
Journal:  Womens Health (Lond)       Date:  2013-09

5.  The Prevalence of the Most Important Risk Factors Associated with Cervical Cancer.

Authors:  Azra Lukac; Nenad Sulovic; Sonja Smiljic; Aleksandra N Ilic; Orhan Saban
Journal:  Mater Sociomed       Date:  2018-06

6.  Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK.

Authors:  J Cuzick; A Castañón; P Sasieni
Journal:  Br J Cancer       Date:  2010-01-26       Impact factor: 7.640

7.  Benefits and harms of cervical screening from age 20 years compared with screening from age 25 years.

Authors:  R Landy; H Birke; A Castanon; P Sasieni
Journal:  Br J Cancer       Date:  2014-02-11       Impact factor: 7.640

8.  What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study.

Authors:  Rebecca Landy; Peter Windridge; Matthew S Gillman; Peter D Sasieni
Journal:  Int J Cancer       Date:  2017-11-10       Impact factor: 7.396

9.  Outcomes of Conservative Management of High Grade Squamous Intraepithelial Lesions in Young Women.

Authors:  Marette H Lee; Sarah J Finlayson; Ksenia Gukova; Gillian Hanley; Dianne Miller; Leslie Ann Sadownik
Journal:  J Low Genit Tract Dis       Date:  2018-07       Impact factor: 1.925

10.  Difference Between Cryotherapy and Follow Up Low Grade Squamous Lesion of Cervix Uteri.

Authors:  Mahira Jahic; Elmir Jahic; Mirsada Mulavdic; Azra Hadzimehmedovic
Journal:  Med Arch       Date:  2017-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.